LeMaitre Vascular (NASDAQ:LMAT) PT Raised to $100.00 at JMP Securities

LeMaitre Vascular (NASDAQ:LMAT) had its price objective hoisted by JMP Securities from $77.00 to $100.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a market outperform rating on the medical instruments supplier’s stock.

Several other analysts also recently commented on the company. Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and upped their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Roth Mkm reaffirmed a buy rating and set a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They set a buy rating and a $105.00 price objective for the company. Barrington Research upped their price objective on LeMaitre Vascular from $79.00 to $92.00 and gave the company an outperform rating in a research note on Friday, August 2nd. Finally, Roth Capital upgraded LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Buy and an average target price of $90.33.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $91.67 on Tuesday. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $91.78. The company has a market capitalization of $2.06 billion, a P/E ratio of 60.71, a PEG ratio of 2.63 and a beta of 0.89. The stock has a 50-day simple moving average of $84.26 and a 200-day simple moving average of $74.40.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The firm’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.37 EPS. As a group, analysts forecast that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock worth $3,714,994 in the last quarter. Company insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the company. Mesirow Institutional Investment Management Inc. acquired a new stake in LeMaitre Vascular during the 4th quarter valued at $8,837,000. Driehaus Capital Management LLC grew its holdings in LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares during the last quarter. F M Investments LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter valued at $7,443,000. Congress Asset Management Co. MA grew its holdings in LeMaitre Vascular by 17.0% during the 4th quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after buying an additional 86,293 shares during the last quarter. Finally, Summit Creek Advisors LLC grew its holdings in LeMaitre Vascular by 37.8% during the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after buying an additional 62,737 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.